Danish medico company Unisense Fertilitech has gained DKK 15m (USD 2.8m) in new capital from its owners and is soon to launch a newly patented instrument, Embryoscope, which can increase the success rate of artificial insemination, reports financial daily newspaper Børsen. Unisense Fertilitech is a subsidiary of Unisense, which owns 50.2% of the shares, while the Employees Capital Pension Fund owns the remaining stake.
Jens K. Gundersen, MD of Unisense Fertilitech and co-founder of parent company Unisense, told Børsen: "In June we expect to get approval from the European authorities for our instrument, Embryoscope, after which we will launch it on the European market. Potential customers are hospitals and fertility clinics. Before the end of the year we also expect to get the instrument certified in the USA where we are collaborating with three or four US fertility clinics on documentation."
The technology in Embryoscope is patented, and Unisense Fertilitech has just bought exclusive rights to a patent on a specific method of analysing images of fertilised eggs from Reify Corp in Boston, US, a move which helps to keep competitors at a distance.
"It is probable that Embryoscope will dramatically increase the success rate for artificial insemination. So we are convinced that we have laid a golden egg. We are now preparing a partial sale of Unisense Fertilitech to a strategic partner with international sales and distribution ," says Gundersen.
Unisense Fertilitech is based in Science Center Skejby in Aarhus, Denmark's second largest city.